Annual CFO
-$24.94 M
-$4.16 M-20.01%
31 December 2023
Summary:
Soleno Therapeutics annual cash flow from operations is currently -$24.94 million, with the most recent change of -$4.16 million (-20.01%) on 31 December 2023. During the last 3 years, it has risen by +$2.83 million (+10.19%). SLNO annual CFO is now -2717.44% below its all-time high of -$885.20 thousand, reached on 31 December 2013.SLNO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$14.93 M
+$2.73 M+15.44%
30 September 2024
Summary:
Soleno Therapeutics quarterly cash flow from operations is currently -$14.93 million, with the most recent change of +$2.73 million (+15.44%) on 30 September 2024. Over the past year, it has dropped by -$8.61 million (-136.40%). SLNO quarterly CFO is now -815.91% below its all-time high of $2.08 million, reached on 31 March 2013.SLNO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$51.42 M
-$8.59 M-20.07%
30 September 2024
Summary:
Soleno Therapeutics TTM cash flow from operations is currently -$51.42 million, with the most recent change of -$8.59 million (-20.07%) on 30 September 2024. Over the past year, it has dropped by -$26.48 million (-106.17%). SLNO TTM CFO is now -2566.26% below its all-time high of $2.08 million, reached on 31 March 2013.SLNO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SLNO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -136.4% | -106.2% |
| 3 y3 years | +10.2% | -117.5% | -85.2% |
| 5 y5 years | -43.5% | -194.1% | -195.9% |
SLNO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -20.0% | +10.2% | -223.1% | +15.4% | -147.4% | at low |
| 5 y | 5 years | -43.5% | +10.2% | -223.1% | +15.4% | -195.9% | at low |
| alltime | all time | -2717.4% | +10.2% | -815.9% | +15.4% | -2566.3% | at low |
Soleno Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.93 M(-15.4%) | -$51.42 M(+20.1%) |
| June 2024 | - | -$17.65 M(+40.9%) | -$42.83 M(+39.3%) |
| Mar 2024 | - | -$12.53 M(+98.4%) | -$30.74 M(+23.3%) |
| Dec 2023 | -$24.94 M(+20.0%) | -$6.31 M(-0.3%) | -$24.94 M(+4.9%) |
| Sept 2023 | - | -$6.33 M(+13.8%) | -$23.77 M(+7.6%) |
| June 2023 | - | -$5.57 M(-17.3%) | -$22.09 M(+4.5%) |
| Mar 2023 | - | -$6.73 M(+30.8%) | -$21.15 M(+1.8%) |
| Dec 2022 | -$20.78 M(-25.2%) | -$5.14 M(+10.5%) | -$20.78 M(-7.6%) |
| Sept 2022 | - | -$4.66 M(+0.8%) | -$22.50 M(-3.2%) |
| June 2022 | - | -$4.62 M(-27.4%) | -$23.25 M(-12.7%) |
| Mar 2022 | - | -$6.36 M(-7.3%) | -$26.64 M(-4.1%) |
| Dec 2021 | -$27.77 M(+10.1%) | -$6.86 M(+27.0%) | -$27.77 M(-0.0%) |
| Sept 2021 | - | -$5.41 M(-32.5%) | -$27.77 M(-2.7%) |
| June 2021 | - | -$8.01 M(+7.0%) | -$28.53 M(+5.5%) |
| Mar 2021 | - | -$7.49 M(+9.0%) | -$27.05 M(+7.3%) |
| Dec 2020 | -$25.22 M(+45.2%) | -$6.87 M(+11.4%) | -$25.22 M(+7.6%) |
| Sept 2020 | - | -$6.16 M(-5.7%) | -$23.43 M(+6.6%) |
| June 2020 | - | -$6.53 M(+15.5%) | -$21.99 M(+13.7%) |
| Mar 2020 | - | -$5.66 M(+11.5%) | -$19.35 M(+11.3%) |
| Dec 2019 | -$17.38 M(+48.7%) | -$5.08 M(+7.6%) | -$17.38 M(+8.4%) |
| Sept 2019 | - | -$4.72 M(+21.2%) | -$16.04 M(+14.6%) |
| June 2019 | - | -$3.89 M(+5.6%) | -$13.99 M(+8.9%) |
| Mar 2019 | - | -$3.69 M(-1.3%) | -$12.85 M(+10.0%) |
| Dec 2018 | -$11.68 M | -$3.74 M(+39.6%) | -$11.68 M(+9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$2.68 M(-2.7%) | -$10.68 M(+6.3%) |
| June 2018 | - | -$2.75 M(+9.1%) | -$10.04 M(-2.4%) |
| Mar 2018 | - | -$2.52 M(-7.8%) | -$10.29 M(+3.4%) |
| Dec 2017 | -$9.95 M(-26.3%) | -$2.73 M(+33.7%) | -$9.95 M(+0.4%) |
| Sept 2017 | - | -$2.04 M(-31.7%) | -$9.91 M(-7.0%) |
| June 2017 | - | -$2.99 M(+37.1%) | -$10.65 M(-9.0%) |
| Mar 2017 | - | -$2.18 M(-18.8%) | -$11.70 M(-13.3%) |
| Dec 2016 | -$13.50 M(+31.1%) | -$2.69 M(-3.5%) | -$13.50 M(-4.9%) |
| Sept 2016 | - | -$2.79 M(-31.0%) | -$14.19 M(-0.5%) |
| June 2016 | - | -$4.04 M(+1.4%) | -$14.26 M(+14.3%) |
| Mar 2016 | - | -$3.98 M(+17.9%) | -$12.47 M(+21.1%) |
| Dec 2015 | -$10.30 M(+129.7%) | -$3.38 M(+18.1%) | -$10.30 M(+21.5%) |
| Sept 2015 | - | -$2.86 M(+27.1%) | -$8.48 M(+23.2%) |
| June 2015 | - | -$2.25 M(+24.4%) | -$6.88 M(+18.9%) |
| Mar 2015 | - | -$1.81 M(+16.2%) | -$5.78 M(+29.0%) |
| Dec 2014 | -$4.48 M(+406.6%) | -$1.56 M(+23.3%) | -$4.48 M(+22.9%) |
| Sept 2014 | - | -$1.26 M(+9.1%) | -$3.65 M(+10.2%) |
| June 2014 | - | -$1.16 M(+127.3%) | -$3.31 M(-4.8%) |
| Mar 2014 | - | -$509.00 K(-29.5%) | -$3.48 M(+293.0%) |
| Dec 2013 | -$885.20 K(-74.7%) | -$722.20 K(-21.8%) | -$885.20 K(+443.1%) |
| Sept 2013 | - | -$924.10 K(-30.2%) | -$163.00 K(-121.4%) |
| June 2013 | - | -$1.32 M(-163.5%) | $761.10 K(-63.5%) |
| Mar 2013 | - | $2.08 M | $2.08 M |
| Dec 2012 | -$3.50 M | - | - |
FAQ
- What is Soleno Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Soleno Therapeutics?
- What is Soleno Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Soleno Therapeutics?
- What is Soleno Therapeutics quarterly CFO year-on-year change?
- What is Soleno Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Soleno Therapeutics?
- What is Soleno Therapeutics TTM CFO year-on-year change?
What is Soleno Therapeutics annual cash flow from operations?
The current annual CFO of SLNO is -$24.94 M
What is the all time high annual CFO for Soleno Therapeutics?
Soleno Therapeutics all-time high annual cash flow from operations is -$885.20 K
What is Soleno Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SLNO is -$14.93 M
What is the all time high quarterly CFO for Soleno Therapeutics?
Soleno Therapeutics all-time high quarterly cash flow from operations is $2.08 M
What is Soleno Therapeutics quarterly CFO year-on-year change?
Over the past year, SLNO quarterly cash flow from operations has changed by -$8.61 M (-136.40%)
What is Soleno Therapeutics TTM cash flow from operations?
The current TTM CFO of SLNO is -$51.42 M
What is the all time high TTM CFO for Soleno Therapeutics?
Soleno Therapeutics all-time high TTM cash flow from operations is $2.08 M
What is Soleno Therapeutics TTM CFO year-on-year change?
Over the past year, SLNO TTM cash flow from operations has changed by -$26.48 M (-106.17%)